Lbp Am Sa Cuts Stake in Bruker Co. (NASDAQ:BRKR)

LBP AM SA trimmed its stake in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 42.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,770 shares of the medical research company's stock after selling 27,092 shares during the quarter. LBP AM SA's holdings in Bruker were worth $2,155,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. True Wealth Design LLC raised its stake in shares of Bruker by 4,636.4% during the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock worth $36,000 after buying an additional 510 shares in the last quarter. Eagle Bay Advisors LLC raised its stake in shares of Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock worth $41,000 after buying an additional 674 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Bruker by 37.5% during the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after buying an additional 248 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Bruker by 47.5% during the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock worth $75,000 after buying an additional 412 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Bruker by 41.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock valued at $78,000 after purchasing an additional 390 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Bruker Trading Down 4.7 %

Bruker stock traded down $2.21 during midday trading on Thursday, reaching $44.47. The stock had a trading volume of 2,253,089 shares, compared to its average volume of 1,295,532. Bruker Co. has a twelve month low of $44.11 and a twelve month high of $94.86. The stock has a market capitalization of $6.75 billion, a PE ratio of 58.51, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The stock's 50-day simple moving average is $52.82 and its 200 day simple moving average is $58.00.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Analysts expect that Bruker Co. will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Monday, March 17th will be given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.45%. The ex-dividend date is Monday, March 17th. Bruker's dividend payout ratio (DPR) is presently 26.32%.

Analyst Ratings Changes

Several equities analysts recently weighed in on BRKR shares. Barclays dropped their price objective on Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Bank of America increased their target price on Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a report on Friday, December 13th. Guggenheim reiterated a "buy" rating on shares of Bruker in a report on Monday, February 24th. UBS Group initiated coverage on Bruker in a report on Tuesday, December 10th. They set a "neutral" rating and a $66.00 target price on the stock. Finally, The Goldman Sachs Group upgraded Bruker from a "sell" rating to a "neutral" rating and set a $60.00 target price on the stock in a report on Thursday, December 5th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $70.50.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.